Nexplanon (etonogestrel implant) / Organon - LARVOL DELTA

Vapocoolant Spray to Reduce Pain With Nexplanon Insertion (clinicaltrials.gov) - P=N/A | N=70 | Recruiting | Sponsor: Queen's Medical Center | Not yet recruiting ➔ Recruiting

Enrollment open • Pain

Localization of a contraceptive implant using a silicon chip-based handheld ultrasound device. (PubMed, Arch Gynecol Obstet) - "This case demonstrates that a semiconductor-based handheld ultrasound can reliably detect a non-palpable contraceptive implant, yielding sonographic images comparable to a standard piezoelectic ultrasound device. The successful localization and removal of the implant using the portable device suggests that this new ultrasound technology can be a valuable tool in obstetric and gynecologic practice for managing challenging implant cases. Its portability and ease of use at the point of care may improve access to timely implant removal in clinic settings, operating theaters, and remote or underserved areas. Wider adoption of this technology, alongside formal studies validating its accuracy, could enhance clinical workflows for contraceptive implant management."

Journal • Anesthesia • Gynecology • Long-acting Reversible Contraceptives • Obstetrics

Effects of the immediate postpartum insertion of the etonogestrel implant on the development of breastfed infants: Results from a randomized controlled trial. (PubMed, Int J Gynaecol Obstet) - P4 | "Immediate postpartum ENG implant insertion did not negatively impact infant development up to 12-15 months."

Journal • Long-acting Reversible Contraceptives

Monolithic Shape-Shifting Absorbable Implants for Long-Term Contraception. (PubMed, bioRxiv) - "As a result, MoSAIC systems can be designed to be smaller, less invasive, and/or longer lasting than current contraceptive implants such as Jadelle® and Nexplanon®. The MoSAIC platform expands access to reversible contraception and supports long-term medication adherence, with the potential to improve health outcomes and quality of life. More broadly, it provides a flexible approach for delivering other potent, low-solubility therapeutics and lays the foundation for a "dose it and forget it" paradigm in chronic disease management, where adherence is designed into the therapy itself."

Journal • Long-acting Reversible Contraceptives

Pain Related to Local Anesthetic Administration for Nexplanon Placement (clinicaltrials.gov) - P=N/A | N=68 | Not yet recruiting | Sponsor: University of California, San Diego

New trial • Anesthesia • Pain

Evaluation of reference ranges of four circulating sex steroids from dried blood spots in women aged 18 to 40 years. (PubMed, J Steroid Biochem Mol Biol) - "Whole blood testosterone (T), androstenedione (A4), 17α hydroxyprogesterone (17OHP), and progesterone (P4) were measured by liquid chromatography-tandem mass spectrometry (LCMS) from dried filter paper blood spots...All sex steroid concentrations were significantly lower in participants taking a systemic hormonal contraceptive (combined oral contraceptive or etonogestrel implant)...These data provide reference ranges for whole blood T, A4, 17OHP and P4 measured by LCMS from dried blood spots from healthy young adult premenopausal women. Small but significant variations were evident according to age, hormonal contraceptive use and menstrual cycle phase."

Journal

RCT Evaluating Standardized Counseling on Early Discontinuation for Irregular Bleeding in Nexplanon Users (clinicaltrials.gov) - P4 | N=348 | Active, not recruiting | Sponsor: Planned Parenthood of the St. Louis Region and Southwest Missouri | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2025 ➔ Dec 2025 | Trial primary completion date: Nov 2024 ➔ Nov 2025

Enrollment closed • Trial completion date • Trial primary completion date • Long-acting Reversible Contraceptives

Evaluation of Immediate Postpartum Long-Acting Reversible Contraception for Reducing Short-Interval Pregnancies. (PubMed, Cureus) - "Providing LARC shortly after delivery shows promise for patient uptake and prevention of SIP among individuals wishing for contraception. Expanded studies are warranted."

Journal • Gynecology • Long-acting Reversible Contraceptives

Menstrual Dysphoria and Preferences for Menstrual Suppression in Transgender and Gender-Diverse Youth. (PubMed, J Pediatr Adolesc Gynecol) - "The study underscores the considerable distress that menstruation can cause in TGD youth. Moreover, the importance of personalized, patient-centered counseling is emphasized, with the objective of empowering individuals to make decisions based on their specific needs."

Journal • CNS Disorders • Long-acting Reversible Contraceptives

Tackling Recurrent Pregnancy in Adolescents Through Postpartum Contraception Counseling (ACOG 2025) - "Exposure of interest was PPC: long-acting reversible contraceptive (LARC) (intrauterine device [IUD], Nexplanon), hormonal (HC: combined hormonal methods, depo injections, and progesterone-only pills), and nonhormonal (NHC: condoms, abstinence, none). Of 395 patients with contraception data, only race/ethnicity correlated with PPC choice. Black adolescents selected HC over LARC over NHC (P=.009). Latinx adolescents selected NHC over LARC over HC (P=.006)."

Long-acting Reversible Contraceptives • Obstetrics

Lack of association between contraception initiation at delivery discharge and 6-week postpartum psychopathology symptoms (ACOG 2025) - "Depression symptomatology was compared across patients who chose local contraception (ie, intrauterine device) versus systemic hormonal contraception (ie, medroxyprogesterone acetate injection, etonogestrel implant, etonogestrel-ethinyl estradiol ring, norelgestromin/ethinyl estradiol transdermal patch, norethindrone pills), and no contraception using chi-squared and multivariable logistic regression. Among 3,644 patients, 57% received contraception at discharge. We did not identify an association between local, systemic, or no contraception and PHQ-9 scores at the 6-week postpartum visit in univariate or multivariable logistic regression analyses. However, odds of moderate/severe depression symptomatology scores were elevated with previous psychiatric diagnosis (odds ratio [OR] 3.58; 95% CI, 2.15–5.97), Black race (OR 2.02; 95% CI, 0.91–4.48), and being separated/divorced/widowed as compared to married/life partnership (OR 5.08; 95% CI, 1.35–19.14)."

CNS Disorders • Depression • Long-acting Reversible Contraceptives • Mental Retardation • Psychiatry

Cost-Effectiveness (CEA) of Etonogestrel Subdermal Implant in a Brazilian Private Health Insurance (ISPOR 2025) - "OBJECTIVES: To evaluate the cost-effectiveness of the etonogestrel implant (EI) compared to monthly and quarterly injectables, hormonal intrauterine device (IUD-h) from the perspective of the Brazilian Private Health Insurance (HMO)... EI proved to be the most effective and cost-effective method among those evaluated, significantly reducing unplanned pregnancies and associated costs. Notably, indirect and social costs related to unintended pregnancies were not considered, suggesting that the economic benefits of EI may be even greater than estimated."

Cost effectiveness • HEOR • Reimbursement • US reimbursement • Long-acting Reversible Contraceptives

One-year continuation of the etonogestrel contraceptive implant initiated with oral emergency contraception. (PubMed, Contraception) - P | "Nearly 60% of participants who chose guideline-supported ENG implant placement at an EC clinical visit continued use at one year."

Journal • Long-acting Reversible Contraceptives

Etonogestrel Implant as Emergency Contraception (clinicaltrials.gov) - P4 | N=12 | Recruiting | Sponsor: University of Colorado, Denver | Trial completion date: Dec 2023 ➔ Dec 2026 | Trial primary completion date: Dec 2023 ➔ Dec 2026

Trial completion date • Trial primary completion date

Pharmacokinetic and clinical associations between doravirine-containing ART and injectable and implantable hormonal contraceptive methods among women living with HIV in South Africa. (PubMed, J Infect Dis) - "We found no detrimental bidirectional drug-drug interactions and few adverse events between doravirine and hormonal contraceptives."

Journal • PK/PD data • Human Immunodeficiency Virus • Infectious Disease • Long-acting Reversible Contraceptives

Effects of hormonal contraception on vocal patterns of captive southern yellow-cheeked gibbons (Nomascus gabriellae). (PubMed, Front Vet Sci) - "As part of our long-term research into the vocal behavior of southern yellow-cheeked gibbons (Nomascus gabriellae) in zoos, we have managed to obtain vocal datasets from four adult contracepted (Nexplanon® and Depo-Provera®) females of this species. These values remained significantly higher than the values at the pre-application level once the effects waned. This study provides the first evidence of changes in the stable vocal patterns of female southern yellow-cheeked gibbons as a consequence of the application of hormonal contraception."

Journal

Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo (clinicaltrials.gov) - P4 | N=790 | Recruiting | Sponsor: Lori Gawron | Trial primary completion date: Jan 2028 ➔ Apr 2028

Trial primary completion date

Difficult Implanon Extraction Resulting in Ulnar Neuropathy: Clinical Insights. (PubMed, Cureus) - "Implanon NXT is a widely used contraceptive implant that is generally inserted and removed safely by primary healthcare providers...In cases where removal proves difficult or complications arise, timely referral to a specialty center is critical. Such referrals ensure that patients receive expert care, potentially mitigating long-term sequelae and optimizing overall outcomes."

Journal • Long-acting Reversible Contraceptives • Pain

Complication of Nexplanon contraceptive implant requiring intramuscular removal from biceps: A Case Report. (PubMed, J Family Med Prim Care) - "This is a case of a Nexplanon implant migration into the biceps brachii muscle, requiring surgical removal. Implants that become non-palpable should be immediately visualized with imaging to prevent further nerve or vascular injury and subsequently be removed."

Journal • Gynecology • Long-acting Reversible Contraceptives • Obstetrics • Orthopedics

Vapocoolant Spray to Reduce Pain With Nexplanon Insertion (clinicaltrials.gov) - P=N/A | N=70 | Not yet recruiting | Sponsor: Queen's Medical Center

New trial • Pain

Same Day Oral EC and Implant Initiation (clinicaltrials.gov) - P=N/A | N=306 | Completed | Sponsor: University of Utah | Active, not recruiting ➔ Completed

Trial completion • Long-acting Reversible Contraceptives

Kuwa Free! - Live Free! (clinicaltrials.gov) - P=N/A | N=700 | Recruiting | Sponsor: University of Alabama at Birmingham | Trial completion date: Mar 2025 ➔ Mar 2026 | Trial primary completion date: Mar 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease

Clinical efficacy of etonogestrel implants on relieving dysmenorrhea in endometriosis and adenomyosis women for up to 3 years. (PubMed, Front Med (Lausanne)) - "Serum CA125 levels dropped, confirming therapeutic efficacy. Etonogestrel implantation significantly alleviated dysmenorrhea symptoms in AM and EM patients."

Journal • Acne Vulgaris • Endometriosis • Gynecology • Women's Health

SCD CURE: Effects of the Contraceptive Implant in Women With Sickle Cell Disease (clinicaltrials.gov) - P4 | N=22 | Recruiting | Sponsor: University of Pennsylvania | Trial completion date: Feb 2025 ➔ Jun 2025 | Trial primary completion date: Feb 2025 ➔ Jun 2025

Trial completion date • Trial primary completion date • Genetic Disorders • Hematological Disorders • Long-acting Reversible Contraceptives • Sickle Cell Disease

Breastfeeding after immediate versus delayed postpartum contraceptive implant placement: a non-inferiority randomized controlled trial. (PubMed, Am J Obstet Gynecol) - "The results demonstrated no clinically important differences in breastfeeding and implant continuation outcomes though our primary outcome exceeded our pre-defined non-inferiority margin. These reassuring data add to the evidence base for supporting etonogestrel implant initiation for breastfeeding people whenever they desire it postpartum."

Head-to-Head • Journal • Long-acting Reversible Contraceptives